Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Subscribe To Our Newsletter & Stay Updated